Previous close | 26.09 |
Open | 26.07 |
Bid | 25.96 x 900 |
Ask | 25.97 x 800 |
Day's range | 25.92 - 26.12 |
52-week range | 21.53 - 32.28 |
Volume | |
Avg. volume | 991,653 |
Market cap | 11.364B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 43.33 |
EPS (TTM) | 0.60 |
Earnings date | 01 Aug 2024 |
Forward dividend & yield | 0.75 (2.87%) |
Ex-dividend date | 01 Apr 2024 |
1y target est | 30.50 |
Key Insights Smith & Nephew's estimated fair value is UK£15.04 based on 2 Stage Free Cash Flow to Equity Current share...
Key Insights Given the large stake in the stock by institutions, Smith & Nephew's stock price might be vulnerable to...
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip